{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "MINI-ABSTRACT: We sought to evaluate patient-reported symptomatic adverse event rates among patients with borderline-resectable pancreatic cancer receiving neoadjuvant therapy on clinical trial (A021501)."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A021501 (Dec 31, 2016-Jan 1, 2019) randomized patients with borderline resectable pancreatic ductal adenocarcinoma"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with borderline resectable pancreatic ductal adenocarcinoma"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized patients with borderline resectable pancreatic ductal adenocarcinoma to 8 doses of mFOLFIRINOX (Arm 1) or 7 doses of mFOLFIRINOX + hypofractionated radiotherapy (Arm 2)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective:: We sought to evaluate symptomatic adverse event (AE) rates among patients with pancreatic cancer receiving neoadjuvant therapy on clinical trial (A021501) using the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Patients completed PRO-CTCAE assessments at baseline, on day 1 of each chemotherapy cycle, and daily during radiotherapy."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "A021501 (Dec 31, 2016-Jan 1, 2019) randomized patients"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 126 patients, 96 (76%) initiated treatment and completed a baseline plus at least 1 post-baseline PRO-CTCAE assessment."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 126 patients, 96 (76%) initiated treatment and completed a baseline plus at least 1 post-baseline PRO-CTCAE assessment."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Decreased appetite was higher in Arm 2 than in Arm 1 ( P =0.0497); no other differences between study arms were observed."
      },
      "Harms": {
        "score": 1,
        "evidence": "Diarrhea and fatigue were the only symptomatic grade 3 or higher AEs identified in at least 10% of patients using CTCAE."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}